Home  »  Stocks to Invest   »  Obalon Therapeutics Inc. (OBLN) stock surges in th...

Obalon Therapeutics Inc. (OBLN) stock surges in the pre-market trading. Why is it so?

Obalon Therapeutics Inc. (OBLN) stock gained by 2.9% at the last trading close while the OBLN stock price kept on rising by 16.94% in the pre-market trading session. Obalon Therapeutics is a San Diego-based company that specializes in the development and commercialization of innovative weight-loss technologies.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Recent Important Events

On April 17, 2021, it was being announced that WeissLaw LLP is reviewing alleged violations of fiduciary responsibility and other legal irregularities by Obalon Therapeutics’ board of directors in conjunction with OBLN’s planned merger with ReShape Lifesciences Inc. ReShape will purchase OBLN in an all-stock deal under the terms of the merger agreement, and OBLN will be renamed ReShape Lifesciences Inc.

Financial Results

Around a month back, OBLN announced its financial results for the fourth quarter and full-year 2020. Given below is the summary.

Fourth Quarter 2020

  • OBLN’s revenue for the fourth quarter of 2020 was $0.1 million, whereas for the fourth quarter 2019 the revenue was $0.8 million with the decrease primarily due to the suspension of operations in the second quarter of 2020.
  • Net loss for the fourth quarter of 2020 was $1.3 million, compared to $4.9 million for the fourth quarter of 2019. Net loss per share for the fourth quarter of 2020 was $0.17, compared to $0.64 for the fourth quarter of 2019.
  • In the fourth quarter of 2020, research and development costs were $0.2 million, decreasing from $1.5 million in the fourth quarter of 2019.
  • In the fourth quarter of 2020, selling, general, and administrative expenses fell to $1.2 million, relative to $3.6 million in the fourth quarter of 2019.

Full year 2020

  • OBLN’s revenue for the full year of 2020 was $1.6 million, compared to $3.3 million for the full year of 2019, with the decrease primarily due to the suspension of operations in the second quarter of 2020. Net loss for the full year of 2020 was $12.3 million, compared to $23.7 million for the full year of 2019. Net loss per share for the full year of 2020 was $1.59, compared to $5.03 for the full year of 2019.
  • The total cost of research and development for the full year of 2020 was $2.5 million, down from $6.9 million in the previous year.
  • For the full year of 2020, selling, general, and administrative expenses fell to $8.8 million, down from $16.7 million in 2019.
  • The operating loss for the full year of 2020 was $12.0 million, compared to $23.2 million in the previous year.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam